I have managed teams working with over 100 companies on 700 projects across 40 therapy areas. Projects have included:1. 5-year support for a leading orphan drug company with a focus on tracking all patients across all centres in 30+ countries to support both their new business targeting and manufacturing planning2. Business and operational plan to support the build of a proprietary drug development business for a major supplier of biologics 3. 3-year business development support for an emerging European pharma company growing the portfolio from 2 to 8 products 4. Combined European regulatory and market access advice for US company prior to acquisition to ensure alignment of their clinical programme5. 5-year support for major academic institution focused on strategic advice and analysis of their royalty revenues 6. Market assessment for device company covering Europe and US to support partnering and IPO 7. Due diligence on 2 US specialty businesses resulting in acquisition by European organisation leading to significant consolidation of the allergy sector 8. Fundamental overview of a range of movement disorder conditions combining clinical and commercial recommendations to support R&D and in-license activities 9. Worked with 2 academic organisations with early technology and data packages resulting in both companies spinning out as SMEs 10. Supported the establishment of US cardiovascular company in Europe (3 year programme) 11. Development of respiratory company’s business development strategy outside the US 12. Development strategy for European dermatology specialty company with recommendations on go/no-go decisions and out-license priorities13. Major evaluation of the cosmetic/aesthetic dermatology business in US and Europe to support investment/divestment decisions 14. Market evaluation and market access evaluation for major biosimilar opportunity in Europe

Set up the company with two colleagues

• Carried out a range of business analytical support for GI disease, dermatology, metabolic disorders & oncology, the latter as part of the merger process. • The support included commissioning and presentation of all strategic market research projects, annual 5 and 10 year forecasts, business development support during major divestment periods, patent expiry modelling and evaluation of in-licensing opportunities.• I was involved in both the GW and SB mergers the former as part of the operational merger team the latter supporting one of their main therapeutic franchises

Project manager for Zantac Line Extension programme and Patent Expiry Working groups

Set up and completed Phase II proof of concept studies for an NCE in Depression

Ran the Phase IV EU studies for Seroxat